CareDx announced at ASN Kidney Week 2025 that it will launch HistoMap Kidney, a tissue‑based gene expression assay that objectively characterizes rejection type and enhances the clinical utility of biopsy results for kidney transplant patients.
The assay complements existing biopsy pathology by providing molecular insights, enabling clinicians to make more precise and timely decisions. It is part of CareDx’s precision medicine strategy to bridge histology with genomics and strengthen its integrated transplant diagnostics ecosystem.
HistoMap Kidney will be available early 2026 through a clinical study, expanding CareDx’s product portfolio and potentially capturing a larger share of the kidney transplant diagnostics market. The announcement signals continued innovation and growth prospects for the company.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.